Michael B. Kays
1989 Infectious Diseases Pharmacotherapy Residency, Medical University of South Carolina
1988 PharmD, Medical University of South Carolina
1985 BS, Pharmacy, St. Louis College of Pharmacy
Dr. Kays' research and clinical practice focus in the area of infectious diseases pharmacotherapeutics. Specifically, he is interested in the pharmacokinetics and pharmacodynamics of antibacterial agents, appropriate dosing of antimicrobial agents, evaluation of investigational antimicrobials through in vitro analyses, development of bacterial resistance, and drug-drug/drug-food interactions involving antimicrobial agents. For the past several years, Dr. Kays' research has focused on determining appropriate dosing of antibacterial agents in special patient populations, including patients who are morbidly obese. One of his primary teaching goals is to teach future and present clinicians how to select antimicrobial therapy using pharmacodynamic principles, integrating knowledge of pharmacokinetics and in vitro activity, and patient-specific factors.
PHRM 865, Integrated Pharmacotherapy V
PHRM 827, Public Health Pharmacy
PHRM 846, Principles of Pharmacokinetics
PHRM 821, Professional Program Laboratory II
PHRM 841, Professional Program Laboratory IV
PHRM 861, Professional Program Laboratory VI
Honors and Credentials
Fellow, American College of Clinical Pharmacy
Dr. Aziz Outstanding Teacher of the Year
Henry W. Heine Memorial Award for Excellence in Undergraduate Teaching
Infectious Disease Clinical Specialist, Eskenazi Health
1. Chung EK, Cheatham SC, Fleming MR, Kays MB. Population pharmacokinetics and pharmacodynamics of doripenem in obese, hospitalized patients. Annals of Pharmacotherapy 2017;51:209-218.
2. Chung EK, Cheatham SC, Fleming MR, Healy DP, Kays MB. Population pharmacokinetics and pharmacodynamics of meropenem in non-obese, obese, and morbidly obese patients. Journal of Clinical Pharmacology 2017;57:356-368.
3. Lewis SJ, Kays MB, Mueller BA. Determination of carbapenem dosing recommendations in SHIFT renal replacement therapy using Monte Carlo simulations. Journal of Clinical Pharmacology 2016;56:1277-1287.
4. Nichols K, Chung EK, Knoderer CA, Dees J, Healy DP, Buenger LE, Crumby AS, Kays MB. Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children. Antimicrobial Agents and Chemotherapy 2016;60:522-531.
5. Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and non-obese patients. Journal of Clinical Pharmacology 2015;55:899-908.
6. Nichols KR, Karmire LC, Cox EG, Kays MB, Knoderer CA. Implementing extended-infusion cefepime as standard of care in a children’s hospital. Annals of Pharmacotherapy 2015;49:419-426.
7. Pence LM, Mock CM, Kays MB, Atkinson KM, Muloma EW, Erdman SM. Correlation of adherence to the 2012 Infectious Diseases Society of America practice guidelines with patient outcomes in the treatment of diabetic foot infections in an outpatient parenteral antimicrobial program. Diabetic Medicine 2014;31:1114-1120.
8. Kays MB, Fleming MR, Cheatham SC, Chung EK, Juenke JM. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Annals of Pharmacotherapy 2014;48:178-186.
9. Cheatham SC, Fleming MR, Healy DP, Chung EK, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese, hospitalized patients. Journal of Clinical Pharmacology 2014;54:324-330.
10. Cheatham SC, Fleming MR, Healy DP, Chung CEK, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. International Journal of Antimicrobial Agents 2013;41:52-56.